28668-07-7

Upstream product

• 5334-38-3 3-methyl-4-nitropyrazole-5-carboxylic acid 
• 7664-93-9 sulfuric acid 
• 4027-57-0 ethyl 5-methyl-2H-pyrazole-3-carboxylate 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 402-61-9 5-methyl-1H-pyrazole-3-carboxylic acid 

Downstream Products

• 5334-36-1 5-methyl-4-nitro-1⁽²⁾H-pyrazole-3-carboxylic acid amide 
• 138836-89-2 ethyl 1-<2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-ribofuranosyl>-5-methyl-4-nitro-1H-pyrazole-3-carboxylate 
• 138836-82-5 ethyl 1-<2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-ribofuranosyl>-3-methyl-4-nitro-1H-pyrazole-5-carboxylate 
• 138856-94-7 N-<2-<5-O--2-deoxy-β-D-ribofuranosyl>-3-methyl-7-oxo-2H-pyrazolo<4,3-d>pyrimidin-5-yl>-2-methylpropanamide 
• 138856-93-6 N-<1-<5-O--2-deoxy-β-D-ribofuranosyl>-3-methyl-7-oxo-1H-pyrazolo<4,3-d>pyrimidin-5-yl>-2-methylpropanamide 
• 138836-87-0 Diisopropyl-phosphoramidous acid (2R,3S,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(5-isobutyrylamino-3-methyl-7-oxo-6,7-dihydro-pyrazolo[4,3-d]pyrimidin-1-yl)-tetrahydro-furan-3-yl ester 2-cyano-ethyl ester 
• 138836-94-9 Diisopropyl-phosphoramidous acid (2R,3S,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(5-isobutyrylamino-3-methyl-7-oxo-6,7-dihydro-pyrazolo[4,3-d]pyrimidin-2-yl)-tetrahydro-furan-3-yl ester 2-cyano-ethyl ester 
• 5399-95-1 7-chloro-3-methyl-1H-pyrazolo<4,3-d>pyrimidine 
• 7057-22-9 7-Amino-3-methylpyrazolo<4,3-d>pyrimidin 
• 77816-07-0 3-methyl-1(2)H-pyrazolo[4,3-d]pyrimidine 
• 28668-16-8 4-amino-5-methyl-1H-pyrazole-3-carboxamide 
• 28668-19-1 3-Methylpyrazolo<4,3-d>pyrimidin-5,7-dion 
• 5399-96-2 3-methyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-thione 
• 5399-94-0 3-methyl-7-oxo-6,7-dihydro-1H-pyrazolo<4,3-d>pyrimidine 

Relevant academic research and scientific papers

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

MACROCYCLES AS PDE1 INHIBITORS

The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF

The present invention provides pyrazoles, isoxazoles, isothiazoles, thiadiazoles, and pyridazines according to Formula I as described herein, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines

An improved synthesis is disclosed for 7-alkylamino-3-methylpyrazolo[4,3-d]pyrimidines, which are known to be potent cytokinin antagonists.